Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ruggieri

Showing results (171-180 of 231) with videos related to

Pageof 24
Sort By:
Clinical Neuropharmacology|January 1, 1994
Clinical implications of sustained dopaminergic stimulationF Stocchi, P N Patsalos, A Berardelli, et al.
Clinical Neuropharmacology|October 23, 1997
The long-duration action of levodopa may be due to a postsynaptic effectL Barbato, F Stocchi, A Monge, et al.
Brain Research|January 3, 2001
Time-course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicityF Fornai, G Battaglia, M Gesi, et al.
Journal of Food Protection|September 21, 2001
Antioxidant properties of Mediterranean spices compared with common food additivesM Martínez-Tomé, A M Jiménez, S Ruggieri, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|August 23, 2001
Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's diseaseB Caronti, G Antonini, C Calderaro, et al.
Neuropsychobiology|January 1, 1982
Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's diseaseS Ruggieri, P Falaschi, M Baldassarre, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|July 19, 2001
The prolonged cortical silent period in patients with Huntington's diseaseN Modugno, A Currà, M Giovannelli, et al.
Current Drug Targets. CNS and Neurological Disorders|May 29, 2003
Recent knowledge on molecular components of Lewy bodies discloses future therapeutic strategies in Parkinson's diseaseF Fornai, P Lenzi, M Gesi, et al.
Neurology|August 3, 1999
A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study GroupA D Korczyn, E R Brunt, J P Larsen, et al.
Annals of the New York Academy of Sciences|July 10, 2002
Striatal postsynaptic ultrastructural alterations following methylenedioxymethamphetamine administrationF Fornai, M Gesi, P Lenzi, et al.
Pageof 24

Showing results (171-180 of 231) with videos related to

Sort By:
Pageof 24
Clinical Neuropharmacology|January 1, 1994
Clinical implications of sustained dopaminergic stimulationF Stocchi, P N Patsalos, A Berardelli, et al.
Clinical Neuropharmacology|October 23, 1997
The long-duration action of levodopa may be due to a postsynaptic effectL Barbato, F Stocchi, A Monge, et al.
Brain Research|January 3, 2001
Time-course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicityF Fornai, G Battaglia, M Gesi, et al.
Journal of Food Protection|September 21, 2001
Antioxidant properties of Mediterranean spices compared with common food additivesM Martínez-Tomé, A M Jiménez, S Ruggieri, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|August 23, 2001
Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's diseaseB Caronti, G Antonini, C Calderaro, et al.
Neuropsychobiology|January 1, 1982
Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's diseaseS Ruggieri, P Falaschi, M Baldassarre, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|July 19, 2001
The prolonged cortical silent period in patients with Huntington's diseaseN Modugno, A Currà, M Giovannelli, et al.
Current Drug Targets. CNS and Neurological Disorders|May 29, 2003
Recent knowledge on molecular components of Lewy bodies discloses future therapeutic strategies in Parkinson's diseaseF Fornai, P Lenzi, M Gesi, et al.
Neurology|August 3, 1999
A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study GroupA D Korczyn, E R Brunt, J P Larsen, et al.
Annals of the New York Academy of Sciences|July 10, 2002
Striatal postsynaptic ultrastructural alterations following methylenedioxymethamphetamine administrationF Fornai, M Gesi, P Lenzi, et al.
Pageof 24